Appointment brings extensive regulatory experience as lead asset ETD001 progresses through Phase 2 clinical trial for treatment of cystic fibrosis Brighton, UK, 11 September 2024: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of those suffering from respiratory disease, today announced the appointment […]
Trial aims to deliver clinical proof-of-concept and assess the safety profile of novel long acting ENaC inhibitor ETD001 ETD001, a CFTR mutation agnostic approach to CF, is focussed on providing a novel treatment for members of the CF community that do not benefit from currently available mutation-targeted therapies Brighton, UK, 23 July 2024: Enterprise Therapeutics […]
Appointments bring additional respiratory and late clinical-stage drug development experience as Company commences Phase 2a clinical trial of its lead asset Brighton, UK, 17 June 2024:Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced the appointment […]
Low doses of ETD001 demonstrate exceptionally long duration of action in sheep model of airway mucus clearance Report in Journal of Cystic Fibrosis discloses best-in-class profile of ETD001 ETD001 scheduled to commence Phase 2 clinical study in people with cystic fibrosis in summer 2024 Brighton, UK, 12 June 2024: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical […]
Round led by new investor Panakes, with participation from all existing investors Funding will support Phase 2a clinical proof of concept trial in cystic fibrosis for a novel first in class ENaC blocker (ETD001) and pipeline expansion Dr Rob Woodman, Partner at Panakes, appointed to the Board of Directors Brighton, UK, 30 January 2024: Enterprise […]
Dr Prasad will lead Enterprise’s development strategy to support the continued advancement of the Company’s respiratory programmes through the clinic Brighton, UK, 8 February 2022: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced it has […]
ETD001 is a novel inhaled, long-acting ENaC inhibitor Therapy applicable to all cystic fibrosis patients, independent of genotype Brighton, UK, 14 June 2021: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced it has successfully dosed […]
Enterprise’s novel TMEM16A potentiator portfolio includes ETD002, a first in class compound which is currently in Phase 1 TMEM16A potentiation is a novel therapeutic approach applicable to all cystic fibrosis patients, independent of CFTR genotype, and may provide benefit in other respiratory diseases Enterprise’s shareholders received an upfront payment of £75 million Brighton, UK, 07 […]
ETD002 is a novel TMEM16A chloride channel potentiator Therapy applicable to all cystic fibrosis patients, independent of genotype Brighton, UK, 17 August 2020: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced it has successfully dosed […]
Dr Morris will lead Enterprise’s therapeutics development strategy and drive the Company’s two lead respiratory programmes through the clinic Brighton, UK, 10 February 2020: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced it has appointed […]
Sussex Innovation Centre,
University of Sussex,
Science Park Square,
Falmer, Brighton, BN1 9SB
info@enterprisetherapeutics.com
+44 (0)1273 234667
